ArticleBMC gastroenterology2014
Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B.
Article in BMC gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.PloS one · 2020Pooled it
- The impact of metabolic dysfunction-associated steatotic liver disease on non-invasive fibrosis scores in patients with chronic hepatitis B: a multicenter retrospective study.BMC gastroenterology · 2026Article
- Assessment of the diagnostic performance and influencing factors of AFP and PIVKA-II in hepatocellular carcinoma.Discover oncology · 2026Article
- Fontan-Associated Liver Disease: Trends Over Time and Relationship With Outcomes.Journal of the American Heart Association · 2025Article
- Survival Rate in Hepatocellular Carcinoma after Surgery and Its Association with Clinicopathological Factors: A Single-Center Report.Middle East journal of digestive diseases · 2025Article
- Taurochenodeoxycholic acid as a sensitive stratification marker for HBV-associated hepatic cirrhosis status has a hepatoprotective effect.Scientific reports · 2025Article
- From Large-Scale Characterization to Subgroup-Specific Predictive Modeling: A Study on the Diagnostic Value of Liver Stiffness Measurements in Focal Liver Lesions.Diagnostics (Basel, Switzerland) · 2025Article
- Assessment of Toxoplasma immunoglobulins, α-fetoprotein, and dopamine sera levels: insights into heroin addicts' characteristics.BMC psychiatry · 2025Article
- Advancements in the diagnosis of biliopancreatic diseases: A comparative review and study on future insights.World journal of gastrointestinal endoscopy · 2025Review
- Targeting AFP-RARβ complex formation: a potential strategy for treating AFP-positive hepatocellular carcinoma.Molecular diversity · 2025Article
- Development and validation of an interpretable machine learning model for predicting the risk of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study.BMC gastroenterology · 2025Article
- Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients-A Cohort from the North-Eastern Part of Romania.Microorganisms · 2023Article
- Prognostic Significance of Alpha-Fetoprotein in Staging of Chronic Hepatitis B Infection.Rwanda journal of medicine and health sciences · 2023Article
- Serum Alpha-Fetoprotein as a Predictor of Liver Fibrosis in HBeAg-Positive Chronic Hepatitis B Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Serum alpha-fetoprotein level is correlated with the level of inflammatory markers in the immune-clearance phase of chronic hepatitis B in Eastern China.American journal of translational research · 2023Article
- Liver transplantation following late-onset hepatic sinusoidal obstruction syndrome occurred beyond 1-year postallogeneic hematopoietic stem cell transplantation.Clinical case reports · 2023Article
- The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt.World journal of surgical oncology · 2022Article
- Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.PloS one · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection is a serious public health problem worldwide. This study aimed to investigate the relationship between serum alpha-fetoprotein (AFP) levels and pathological stages of liver biopsy in patients with chronic hepatitis B (CHB).
methodsThe study included 619 patients who were diagnosed with CHB from March 2005 to December 2011. AFP levels were measured by electrochemiluminescence. Liver biopsy samples were classified into five levels of inflammation (G) and fibrosis (S) stages, according to the Chinese guidelines for prevention and treatment of viral hepatitis. Two multivariable ordinal regression models were performed to determine associations between AFP, GGT, and APRI (AST/PLT ratio) and stages of inflammation and fibrosis.
resultsSignificant positive and moderate correlations were shown between AFP levels and inflammation stages and between AFP levels and fibrosis stages (ρ = 0.436 and 0.404, p < 0.001). Median values of AFP at liver fibrosis stages S0-1, S2, S3, and S4 were 3.0, 3.4, 5.4, and 11.3 ng/ml, respectively, and median APRI (AST/PLT ratio) was 0.41. Receiver operating characteristic (ROC) curve analyses revealed that the areas under the curves (AUCs) were 0.685, 0.727, and 0.755 (all p <0.001) for judging inflammation stages of G ≥ 2, G ≥ 3, G = 4 by AFP; and 0.691, 0.717, and 0.718 (all p <0.001) for judging fibrosis stages of S ≥ 2, S ≥ 3, and S = 4 by AFP. APRI levels showed significant positive and moderate correlations with inflammation stages (ρ = 0.445, p < 0.001). AST, GGT, and APRI levels showed significant positive but very weak to weak correlations with fibrosis stages (ρ = 0.137, 0.237, 0.281, p < 0.001).
conclusionsSerum AFP levels increased as pathological levels of inflammation and fibrosis increased in CHB patients. Our data showed the clinical significance of serum AFP levels in diagnosing liver inflammation and fibrosis. Assessment of liver pathology may be improved by creating a predictive mathematical model by which AFP levels with other biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.